Teva won't owe $235M penalty in Coreg 'carve-out' fight with GlaxoSmithKline
admin 29th March 2018 Uncategorised 0Prove it, GlaxoSmithKline. So says a judge in the Coreg patent case that last year ended in a $235 million judgment against generics maker Teva. A judge ruled in Coreg’s patent “carve-out” case that GSK didn’t bring enough evidence to show that Teva persuaded doctors to prescribe the med for indications still protected by patents.
More: Teva won't owe 5M penalty in Coreg 'carve-out' fight with GlaxoSmithKline
Source: fierce